Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last year is […]

Related Keywords

United States , America , Arthura Levin , Sarah Boyce , Avidity Biosciences Inc , Vanguard Group Inc , Needham Company , Nasdaq , Cantor Fitzgerald , Avoro Capital Advisors , Pricet Rowe Associates Inc , Avidity Biosciences , Get Free Report , Biosciences Trading Down , Director Arthur , Capital Advisors , Get Free , Avidity Biosciences Daily ,